Stoke Therapeutics Inc. (NASDAQ: STOK) announced updated timelines for its Phase 3 EMPEROR study of zorevunersen, an investigational treatment for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE